Wilson Therapeutics AB is a biopharmaceutical company founded in 2012 and based in Sweden focused on developing novel treatments for Wilson Disease, a rare genetic disease that affects approximately 1 in 15,000.
Wilson Therapeutics' lead compound, WTX101, is the proprietary bis-choline salt of tetrathiomolybdate. Tetrathiomolybdate is a novel de-coppering agent - meaning it reduces the body's level of copper - with high affinity and selectivity for copper. Tetrathiomolybdate has been tested in several clinical trials in Wilson Disease where it has been shown to rapidly lower copper levels, stabilizing neurological function and reducing risk of further neurological deterioration after initiation of treatment in patients with Wilson Disease.
Previous studies with tetrathiomolybdate in oncology patients have demonstrated that once-daily dosing is highly effective at reducing copper levels. A once daily dosing regimen is expected to translate into improved patient compliance in Wilson Disease patients and therefore fewer treatment failures.
Wilson Therapeutics is committed to advancing WTX101 through clinical trials with the aim of helping to improve the lives of patients with Wilson Disease.
Mr. Jonas Hansson
Chief Executive Officer
Västra Trädgårdsgatan 15
SE-111 53 Stockholm